

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP05/002230

International filing date: 03 March 2005 (03.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB  
Number: 0406894.6  
Filing date: 26 March 2004 (26.03.2004)

Date of receipt at the International Bureau: 08 April 2005 (08.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

PCT/EP200 5/ 0 0 2 2 3 0



PCT/EP200 5/ 0 0 2 2 3 0



INVESTOR IN PEOPLE


The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*William Morell*

Dated 17 March 2005



25MAR04 EBB4363-1 002093  
POL/7700 0.00-0406894.6 NONE

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

1. Your reference

PPD 70440/GB

2. Patent application number

(The Patent Office will fill in this part)

0406894.6

26 MAR 2004

3. Full name, address and postcode of the or of each applicant (underline all surnames)

SYNGENTA PARTICIPATIONS AG  
Intellectual Property Department  
Schwarzwaldallee 215  
4058 Basel  
SWITZERLAND

Patents ADP number (if you know it)

8029555001

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

PROCESS

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Jane Elizabeth SWIFT  
Intellectual Property Department  
Syngenta Limited  
Jealott's Hill International Research Centre  
PO Box 3538  
Bracknell, Berkshire, RG42 6YA  
UNITED KINGDOM

Patents ADP number (if you know it)

8029563001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

YES (b)

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document.

Continuation sheets of this form 06  
Description  
Claim(s) 01  
Abstract 00  
Drawing(s) 00

10. If you are also filing any of the following, state how many against each item.

Priority documents  
Translations of priority documents  
Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)  
Request for preliminary examination and search (*Patents Form 9/77*)  
Request for substantive examination (*Patents Form 10/77*)  
Any other documents (*please specify*)

11.

I/We request the grant of a patent on the basis of this application.

SYNGENTA PARTICIPATIONS AG  
Signature M. ARUDD  
Authorised Signatory

Date 26 MARCH 2004

12. Name and daytime telephone number of person to contact in the United Kingdom

Margaret Ann RUDD

**Warning**

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*


**Notes**

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.


PROCESS

The present invention relates to a novel method for reducing the cyanide content of a mesotrione sample.

Mesotrione (2-(2'-nitro-4'-methylsulphonyl benzoyl)-1,3-cyclohexanedione) is a selective corn herbicide and has the structure of formula (I)



Mesotrione is prepared by reacting 2-nitro-4-methylsulphonyl benzoyl chloride with cyclohexanedione to give the enol ester, followed by a rearrangement reaction to give mesotrione, as shown in the following reaction scheme:



2-Nitro-4-methylsulphonyl benzoyl chloride is prepared from the corresponding benzoic acid, which in turn is prepared by oxidation of 2-nitro-4-methylsulphonyl toluene. More details on the preparative route may be found in US4695673.

During the rearrangement process, the mesotrione sample is contaminated with cyanide residues from the acetone cyanohydrin catalyst. It is therefore an object of the present invention to provide a simple, but effective method for reducing the level of cyanide residues in the mesotrione sample to an acceptable level.

It has surprisingly been found that adjusting the pH of a mesotrione sample in aqueous solution has a significant impact on the resulting cyanide levels.

Accordingly the present invention provides a method for reducing the cyanide levels in a mesotrione sample, said method comprising:

- (i) taking an aqueous solution of the mesotrione sample in an aqueous solvent,
- 5 (ii) adjusting the pH of said aqueous solution to a value of 9.5 or higher, and
- (iii) crystallising the mesotrione out of solution.

In one embodiment of the invention, the mesotrione sample has previously been isolated, and the aqueous solution is formed by dissolving the isolated sample in an aqueous solvent.

10 In a second embodiment of the invention, the mesotrione sample has not previously been isolated and remains dissolved in the aqueous solvent used in the condensation/rearrangement reaction described above.

The aqueous solvent may be selected from the group consisting of water and a water soluble solvent, such as acetonitrile, triethylamine, methanol, ethanol, acetone.  
15 Preferably, the aqueous solvent is water. The mesotrione sample is suitably dissolved in the aqueous solvent to give a solution concentration of from 1% to 30%, suitably from 5% to 15%, and preferably from 8% to 11%.

Suitably, the pH of the aqueous solution is raised to a pH of at least 11, and preferably at least 11.5. Suitably, the aqueous mesotrione sample is held at a pH of at  
20 least 9.5 for at least 5 minutes, suitably at least 15 minutes and preferably at least 30 minutes.

Suitably, the temperature of the aqueous solution should not be greater than 30°C.

The crystallisation is carried out according to standard laboratory procedures. For example, for a batch crystallisation, the final pH is adjusted from its starting value of 9.5  
25 or higher to pH 2.5 by charging hydrochloric acid to the crystalliser. The hydrochloric acid should be charged in a manner to ensure adequate mixing. The crystallisation process may also be carried out as a semi-batch or continuous process. The crystallisation step may also include a nitrogen sparging step, wherein nitrogen is bubble through the crystallisation vessel in a continuous fashion and sent to a scrubber.

30 The method of the invention may further include a distillation step to remove solvents when the mesotrione sample has not previously been isolated (i.e. the second embodiment of the invention). The distillation step may be carried out either before or after adjusting the pH to 9.5 or higher. The distillation step is suitably carried out using a sufficient amount of steam to remove the solvents from the aqueous solution.

In one embodiment of the invention, the method reduces the cyanide levels in the mesotrione sample to 150ppm or less, suitably 100ppm or less and preferably 50ppm or less.

The invention will now be described further with reference to the following  
5 examples, which are illustrative but not limiting of the invention.

### Example 1

Wet paste mesotrione that was high in total CN was subjected to different treatments in an effort to reduce the total CN content. The results are shown in Table 1.

<b>Table 1</b>				
<b>Example No.</b>	<b>Treatment</b>	<b>Original Cyanide Content (PPM)</b>	<b>Cyanide Content after Treatment (PPM)</b>	<b>% reduction in Cyanide content</b>
1A	Mesotrione was placed in water to make an aqueous solution at a concentration of ~10%, pH was adjusted to >13, ACN was charged, and the mixture was then batch crystallised following standard lab procedures.	546	15	97%
1B	Mesotrione was placed in water to make an aqueous solution at a concentration of ~10%, pH was adjusted to 11.3, ACN was charged, and the mixture was batch crystallised following standard lab procedures.	1114	557	50%
1C	Mesotrione was placed in water to make an aqueous solution at a concentration of ~10%, pH was adjusted to >13, ACN was charged, and the mixture was batch crystallised following standard lab procedures.	1114	50	96%
1D	Mesotrione was placed in water to make an aqueous solution at a concentration of ~10%, pH was adjusted to 11.3, ACN was charged, and the mixture was batch crystallised following standard lab procedures.	690	150	78%
1E	Mesotrione was placed in water to make an aqueous solution at a concentration of ~10%, pH was adjusted to 12-13, ACN was charged, and the mixture was batch crystallised following standard lab procedures.	690	170	75%

Example 2

Mesotrione was crystallised from samples taken from the plant during the solvent distillation. Samples were taken from the same batch after both 4500 lbs steam (distillation not finished) and 5000 lbs steam (distillation finished) had been used during the distillation process. The pH of the sample was adjusted and the samples were crystallised via standard lab procedures. Total CN content was measured by titration of the wet paste. The results are given in Table 2.

<b>Table 2</b>			
<b>Example No.</b>	<b>Distillation Complete?</b>	<b>Starting pH of crystallisation</b>	<b>Total CN of wet paste (PPM)</b>
2A	Yes	5.0	594
2B	No	9.5	278
2C	Yes	9.5	651
2D	No	11.1	120
2E	Yes	11.1	26
2F	No	12.8	121
2G	Yes	12.8	20

Example 3

Mesotrione was crystallised from samples taken from the plant during the solvent distillation. The effects of varying the starting pH of the crystallisation and purging the headspace of the crystallisation vessel with nitrogen were looked at. Samples were taken from the same batch after both 4500 lbs steam (distillation not finished) and 5045 lbs steam (distillation finished) has been used during the distillation. The pH of the sample was adjusted and the samples were crystallised via standard lab procedures. Total CN was measured by titration of the wet paste or filtrate. The results are shown in table 3.



<b>Table 3</b>					
<b>Example No.</b>	<b>Distillation Complete</b>	<b>Starting pH of crystallisation</b>	<b>N<sub>2</sub> purge?</b>	<b>Total CN content of wet paste (PPM)</b>	<b>% reduction in cyanide content from control</b>
3A	No	5.2	No	311	Control
3B	Yes	5.2	No	236	Control
3C	No	9.5	No	91	70
3D	Yes	9.5	No	63	74
3E	No	11.0	No	20	94
3F	Yes	11.0	No	50	79
3G	No	13	No	15	95
3H	Yes	13	No	56	76
3I	No	5.2	Yes	294	5
3J	No	11.0	Yes	46	85
3K	No	11.3	Yes	15	95

Example 4

5 This example looks at the cyanide content of mesotrione crystallised from different feed pH in a continuous crystallisation. The results are shown in Table 4.

<b>Table 4</b>			
<b>Sample</b>	<b>pH of feed to crystalliser</b>	<b>Total CN (ppm)</b>	<b>% Reduction in Cyanide Content from Control</b>
7 <sup>th</sup> (final) sample from crystalliser	5.0	217	Control
7 <sup>th</sup> (final) sample from crystalliser	5.0	181	Control
7 <sup>th</sup> (final) sample from crystalliser	11	15	92-93
Final sample from crystalliser	11	15	92-93
Final sample from crystalliser	11	15	92-93
Final sample from crystalliser	9.5	15	92-93

Example 5

10 Mesotrione was produced from the acid chloride by a standard condensation/rearrangement reaction. After the condensation/rearrangement reaction, water was added and the pH was adjusted to >11 and held for ½ hour. The pH was then adjusted to ~5, the mixture distilled and then batch crystallised from either pH 5 or 9.5. The results are shown in Table 5.

<b>Table 5</b>			
<b>Example No.</b>	<b>pH held at after condensation/rearrangement reaction</b>	<b>Starting pH of crystallisation</b>	<b>Total CN in mesotrione (ppm)</b>
5A	11.9	5.0	15
5B	11.3	9.5	40

Example 6

- 5 A large sample of mesotrione was obtained at the end of the distillation. This sample was divided into aliquots which were adjusted to a pH >11. A series of batch samples were made up and held agitated at the given pH for the amount of time specified in the table before being quickly adjusted to pH 2.4, filtered, washed and submitted for total cyanide analysis. The results are shown in Table 6.

<b>Table 6</b>			
<b>Example No.</b>	<b>Starting pH</b>	<b>Time kept at starting pH (min)</b>	<b>Total CN of mesotrione (ppm)</b>
6A	11.6	0	111
6B	11.3	5	76
6C	11.5	10	72
6D	11.6	15	73
6E	11.5	20	55
6F	11.5	25	72
6G	11.4	30	76
6H	11.7	60	15
6I	12.3	90	15

Claims

1. A method for reducing the cyanide levels in a mesotrione sample, said method comprising:
  - 5 (i) taking an aqueous solution of the mesotrione sample in an aqueous solvent,
  - (ii) adjusting the pH of said aqueous solution to a value of 9.5 or higher, and
  - (iii) crystallising the mesotrione out of solution.
- 10 2. The method of claim 1, wherein the mesotrione sample has previously been isolated and is redissolved in an aqueous solvent.
3. The method of claim 1, wherein the mesotrione sample has not previously been isolated and is already present as an aqueous solution in an aqueous solvent.
- 15 4. The method of claim 3, which further includes a distillation step.
5. The method of claim 4, wherein the distillation step is carried out prior to adjusting the pH of the aqueous solution to a value of 9.5 or higher.
- 20 6. The method of claim 4, wherein the distillation step is carried out after adjusting the pH of the aqueous solution to a value of 9.5 or higher.
7. The method according to any one of claim 1 to 6, wherein the crystallisation step also includes a nitrogen sparging step.
- 25 8. A method according to any one of claims 1 to 7, wherein the cyanide levels in the mesotrione sample are reduced to 150ppm or less.